Condition: Primary Mitochondrial Disease · Sponsor: Pharming Technologies B.V.
The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.
This description comes directly from the study's public registry record.
Communication Manager · +31 71 524 7400 · medinfo@pharming.com
Always discuss trial participation with your own doctor first.
| University of California, Irvine - ALS & Neuromuscular Center | Orange, California, United States | Recruiting |
| The Regents of the University of California - San Diego | San Diego, California, United States | Recruiting |
| UCSF Movement Disorders Clinic | San Francisco, California, United States | Not Yet Recruiting |
| Children's Hospital Colorado - Center for Cancer and Blood Disorders (CCBD) - Anschutz Medical Campus Location | Aurora, Colorado, United States | Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Not Yet Recruiting |
| Novel Clinical Research Center, LLC | Miami, Florida, United States | Recruiting |
| Rare Disease Research, LLC | Atlanta, Georgia, United States | Recruiting |
| IU Health University Hospital | Indianapolis, Indiana, United States | Not Yet Recruiting |
| Johns Hopkins University School of Medicine | Baltimore, Maryland, United States | Not Yet Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Washington University School of Medicine - Center for Advanced Medicine (CAM) - Neuroscience Center | St Louis, Missouri, United States | Not Yet Recruiting |
| Tekton Marlboro Neurology | Marlboro, New Jersey, United States | Recruiting |
+ 43 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05650229